- This event has passed.
Prosem Lecture: Language Measures Across the Spectrum of Alzheimer’s Disease and Related Dementias (ADRD)
April 18, 2022 @ 12:00 pm - 1:00 pm
Presenter: Kimberly Mueller, Ph.D., CCC-SLP, Assistant Professor, Department of Communication Sciences and Disorders, University of WI-Madison
Topic: Language Measures Across the Spectrum of Alzheimer’s Disease and Related Dementias (ADRD)
Madeline R. Hale, MS/PhD SLP 1st Year Graduate Student
Research Assistant, Cognitive-Communication in Aging and Neurogenic Disorders Laboratory (CCANDL)
UW Madison Department of Communication Sciences and Disorders
Leah Sanson-Miles, Lab Manager and Research Specialist
CCANDL, UW Madison Department of Communication Sciences and Disorders
Advances in neuroimaging and fluid-based biomarkers have provided a new window of opportunity in Alzheimer’s disease (AD) research: it is now possible, in research, to know who has AD neuropathology well before the onset of symptoms. However, brain imaging and fluid assays are expensive and inaccessible, and do not predict when someone will exhibit signs and symptoms of dementia. Furthermore, the discovery of AD biomarkers has spurred a multitude of clinical drug trials targeting amyloid plaques and tau tangles; although some of these drugs, such as aducanumab (Aduhelm™), have been shown to effectively remove amyloid plaques, their clinical benefit remains questionable and controversial. As a result, sensitive measures of cognitive and functional decline are needed for disease monitoring and response to treatment in clinical trials. The Cognitive-Communication in Aging and Neurogenic Disorders Lab (CCANDL) works toward developing sensitive measures using existing cognitive tests and language samples to meet this need. In this talk, we will describe methodology including language transcription and coding, item-level and latent profile analyses, and linear mixed effects models. Biomarker acquisition procedures will be described from the research coordinator’s perspective. Finally, we will discuss how we are applying these methods to capture moments of lucidity in individuals living with dementia who are nearing end of life.
This work was supported by NIH-R01 AG070940 (Mueller); R01 AG027161 (Johnson); R01 AG021155 (Johnson); R01 AG054059 (Gleason); R21AG069827 (Gilmore-Bykovskyi)
Watch Presentation Recording